We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.34B
AUM Growth
+$471M
Cap. Flow
+$471M
Cap. Flow %
20.11%
Top 10 Hldgs %
49.6%
Holding
148
New
13
Increased
17
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$59.2M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$51.5M
3
SWTX
SpringWorks Therapeutics
SWTX
+$33.1M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$25.3M
5
KLRS
Kalaris Therapeutics
KLRS
+$22M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$92.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$87.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$28.5M
4
CYTK icon
Cytokinetics
CYTK
+$13.2M
5
BLU
BELLUS Health Inc.
BLU
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 77.68%
2 Consumer Discretionary 2.9%
3 Financials 0.65%
4 Consumer Staples 0.17%
5 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
51
Aurinia Pharmaceuticals
AUPH
$1.92B
$7.52M 0.32%
1,000,000
– –
OMEG
52
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.45M 0.32%
750,000
– –
ONC
53
CALL
BeOne Medicines Ltd
ONC
$33.9B
$6.74M 0.29%
+50,000
New +$8.59M
DYN icon
54
Dyne Therapeutics
DYN
$4.11B
$6.67M 0.28%
525,000
– –
YMAB
55
DELISTED
Y-mAbs Therapeutics
YMAB
$5.77M 0.25%
400,000
– –
IMA
56
ImageneBio Inc
IMA
$65.3M
$5.5M 0.23%
129,126
– –
TRML
57
DELISTED
Tourmaline Bio
TRML
$5.43M 0.23%
206,426
– –
KRON
58
DELISTED
Kronos Bio
KRON
$5.17M 0.22%
1,542,954
– –
LYEL icon
59
Lyell Immunopharma
LYEL
$318M
$5.13M 0.22%
35,000
– –
ACHL
60
DELISTED
Achilles Therapeutics
ACHL
$5.1M 0.22%
2,255,375
– –
RXRX icon
61
Recursion Pharmaceuticals
RXRX
$1.58B
$4.79M 0.2%
450,000
– –
ALXO icon
62
ALX Oncology
ALXO
$261M
$4.79M 0.2%
500,000
– –
OVID icon
63
Ovid Therapeutics
OVID
$424M
$4.6M 0.2%
2,500,000
– –
EXAI
64
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.52M 0.19%
550,000
– –
NTRA icon
65
Natera
NTRA
$35.7B
$4.38M 0.19%
+100,000
New +$4.76M
RNAM
66
DELISTED
Avidity Biosciences
RNAM
$4.08M 0.17%
250,000
– –
OTLY
67
Oatly Group
OTLY
$480M
$3.94M 0.17%
75,000
– –
CNCE
68
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.84M 0.16%
+573,062
New +$3.47M
THRD
69
DELISTED
Third Harmonic Bio
THRD
$3.79M 0.16%
+200,000
New +$3.6M
MIR icon
70
Mirion Technologies
MIR
$3.63B
$3.73M 0.16%
500,000
– –
PFTA
71
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.71M 0.16%
380,000
– –
SQZ
72
DELISTED
SQZ Biotechnologies Company
SQZ
$3.66M 0.16%
1,606,309
– –
NBTX
73
Nanobiotix
NBTX
$1.87B
$3.54M 0.15%
1,000,000
– –
CYPH
74
Cypherpunk Technologies Inc
CYPH
$62.8M
$3.52M 0.15%
400,000
– –
NBP
75
NovaBridge Biosciences American Depositary Shares
NBP
$191M
$3.41M 0.15%
850,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2022 Portfolio in Review

As of Q3 2022, Artal Group held 148 positions worth $2.34B, up 25% from $1.87B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $471M of net new capital in Q3 2022, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was argenx, an estimated $92.6M trimmed.

  • Artal Group's largest Q3 2022 buy was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q3 2022, an estimated $51.5M increase.
  • Artal Group's biggest Q3 2022 reduction was argenx, cutting an estimated $92.6M.
  • Artal Group fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $87.5M.
  • Artal Group's ten largest holdings make up 50% of its $2.34B portfolio in Q3 2022.
  • Artal Group opened 13 new positions and closed 13 in Q3 2022.
  • Artal Group's portfolio value rose 25% quarter-over-quarter to $2.34B.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.